Study finds new ideas for leukemia treatment

Share This Post

A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjusting the bone marrow microenvironment, it can inhibit leukemia cells and stimulate normal blood cell production. This difference is The indirect treatment strategy of the current standard treatment seems to have advantages, not only the outside but also the inside. (Nat Cell Biol. 2017; 19: 1336-1347. Doi: 10.1038 / ncb3625.)

Acute myeloid leukemia (AML) is characterized by the generation of heterogeneous leukemia cells. Patients suffer from severe infection and anemia due to insufficient production of normal red blood cells. Conventional standard treatment is focused on killing leukemia cells with firepower, ignoring the production of healthy red blood cells.

Based on the observation of leukemia patients, the researchers collected a large number of bone marrow samples from leukemia patients for research, compared and imaged healthy cells in the bone marrow and leukemia cells, and discovered this effect of fat cells. Through in vitro cell culture and transplantation tumor model experiments, the researchers found that acute myeloid leukemia cells specifically destroyed the  microenvironment of fat cells in the bone marrow, resulting in an unbalanced regulation of hematopoietic stem cells and progenitor cells and curbing the production of normal blood cells in the bone marrow.

The study revealed for the first time this relationship between the generation of adipocytes in the bone marrow and normal bone marrow erythrocytes. This effect is not only due to the hematopoietic microenvironment of the bone marrow, that is, the niche is crowded, but also the role of adipocytes in the differentiation process. The limiting effect of leukemia cells. This discovery provides new treatment ideas for myeloid leukemia and is expected to improve the symptoms of failure in patients with myeloid leukemia.

Supported by a drug that promotes the production of fat cells, the fat cells in the bone marrow successfully squeezed away the leukemia cells, making room for healthy blood cell production and clearing the portal. In vitro experiments, PPARγ inhibitors can induce the generation of bone marrow adipocytes. By changing the bone marrow microenvironment, it provides vitality for healthy blood cell production and at the same time inhibits the formation of leukemia cells, which may provide a new way of indirect treatment for acute myeloid leukemia. This indirect treatment strategy should be more promising than standard treatments, which have not made much progress over the past few decades.

The researchers pointed out that the focus of the existing standard treatment is to kill tumor cells, change the way of thinking, and adopt different strategies to change the survival environment of cancer cells to achieve therapeutic effects. While suppressing cancer cells, it strengthens healthy cells so that they can regenerate in a new environment induced by drugs. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy